1. Home
  2. GENC vs MDWD Comparison

GENC vs MDWD Comparison

Compare GENC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gencor Industries Inc.

GENC

Gencor Industries Inc.

HOLD

Current Price

$13.53

Market Cap

205.4M

Sector

Industrials

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$17.94

Market Cap

224.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GENC
MDWD
Founded
N/A
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
205.4M
224.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
GENC
MDWD
Price
$13.53
$17.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$16.00
$37.50
AVG Volume (30 Days)
27.1K
129.1K
Earning Date
12-09-2025
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
7.92
N/A
EPS
1.07
N/A
Revenue
$115,437,000.00
$20,932,000.00
Revenue This Year
N/A
$12.77
Revenue Next Year
N/A
$23.36
P/E Ratio
$12.66
N/A
Revenue Growth
2.01
6.15
52 Week Low
$10.80
$14.14
52 Week High
$17.40
$22.51

Technical Indicators

Market Signals
Indicator
GENC
MDWD
Relative Strength Index (RSI) 51.92 48.68
Support Level $13.34 $16.25
Resistance Level $14.13 $18.73
Average True Range (ATR) 0.39 0.82
MACD -0.04 0.08
Stochastic Oscillator 32.55 50.82

Price Performance

Historical Comparison
GENC
MDWD

About GENC Gencor Industries Inc.

Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: